Fig. 5From: Identification and validation of tissue or ctDNA PTPRD phosphatase domain deleterious mutations as prognostic and predictive biomarkers for immune checkpoint inhibitors in non-squamous NSCLCctDNA PTPRD phosphatase-mut was a predictive biomarker for ICIs in ns-NSCLC. a, b PFS (a) and OS (b) HR forest plot of Atezolizumab in different subgroups in validation cohort 3. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001Back to article page